ArticleNPJ precision oncology2023

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.

Maysa M Abu-Khalaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.